|
| 36124689 | Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group. | Neuro Oncol | 2023 |
| 35652336 | Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. | Neuro Oncol | 2023 |
| 36335802 | The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. | Neoplasia | 2023 |
| 36124689 | Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group. | Neuro Oncol | 2023 |
| 37727849 | Embryonal tumor with multilayered rosettes: Overview of diagnosis and therapy. | Neurooncol Adv | 2023 |
| 36516489 | Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group. | Neoplasia | 2023 |
| 37727849 | Embryonal tumor with multilayered rosettes: Overview of diagnosis and therapy. | Neurooncol Adv | 2023 |
| 35652336 | Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. | Neuro Oncol | 2023 |
| 36516489 | Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group. | Neoplasia | 2023 |
| 36335802 | The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. | Neoplasia | 2023 |
| 34802040 | Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. | Lab Invest | 2022 |
| 35901835 | Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. | Lancet Oncol | 2022 |
| 35821675 | Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. | Neurooncol Adv | 2022 |
| 36335125 | Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas. | Nat Commun | 2022 |
| 36550163 | Publisher Correction: Epigenetic alterations of repeated relapses in patient-matched childhood ependymomas. | Nat Commun | 2022 |
| 34989626 | Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report. | Neuroradiol J | 2022 |
| 34802040 | Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. | Lab Invest | 2022 |
| 35182954 | Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. | Transl Oncol | 2022 |
| 35179058 | Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy. | J Oncol Pharm Pract | 2022 |
| 35821675 | Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. | Neurooncol Adv | 2022 |
| 36550163 | Publisher Correction: Epigenetic alterations of repeated relapses in patient-matched childhood ependymomas. | Nat Commun | 2022 |
| 36335125 | Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas. | Nat Commun | 2022 |
| 35901835 | Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. | Lancet Oncol | 2022 |
| 35182954 | Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma. | Transl Oncol | 2022 |
| 35179058 | Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy. | J Oncol Pharm Pract | 2022 |
| 34989626 | Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report. | Neuroradiol J | 2022 |
| 33381908 | The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective. | Pediatr Blood Cancer | 2021 |
| 34053821 | Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review. | J Clin Neurosci | 2021 |
| 34344600 | Corrigendum to "Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review" [J. Clin. Neurosci. 89 (2021) 405-411]. | J Clin Neurosci | 2021 |
| 34133064 | Gadolinium is not necessary for surveillance MR imaging in children with chiasmatic-hypothalamic low-grade glioma. | Pediatr Blood Cancer | 2021 |
| 33358190 | Corrigendum to "Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors" [Cancer Lett. 493 (2020) 197-206]. | Cancer Lett | 2021 |
| 33381908 | The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective. | Pediatr Blood Cancer | 2021 |
| 34719887 | Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. | Adv Sci (Weinh) | 2021 |
| 34719887 | Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. | Adv Sci (Weinh) | 2021 |
| 34133064 | Gadolinium is not necessary for surveillance MR imaging in children with chiasmatic-hypothalamic low-grade glioma. | Pediatr Blood Cancer | 2021 |
| 34344600 | Corrigendum to "Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review" [J. Clin. Neurosci. 89 (2021) 405-411]. | J Clin Neurosci | 2021 |
| 34053821 | Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review. | J Clin Neurosci | 2021 |
| 33358190 | Corrigendum to "Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors" [Cancer Lett. 493 (2020) 197-206]. | Cancer Lett | 2021 |
| 32383818 | Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. | Pediatr Blood Cancer | 2020 |
| 31948735 | Genetics of Common Pediatric Brain Tumors. | Pediatr Neurol | 2020 |
| 32383818 | Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. | Pediatr Blood Cancer | 2020 |
| 32891713 | Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors. | Cancer Lett | 2020 |
| 31948735 | Genetics of Common Pediatric Brain Tumors. | Pediatr Neurol | 2020 |
| 32891713 | Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors. | Cancer Lett | 2020 |
| 31287992 | A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. | Cancer Cell | 2019 |
| 31693904 | Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. | Cell Rep | 2019 |
| 31287992 | A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. | Cancer Cell | 2019 |
| 31693904 | Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. | Cell Rep | 2019 |
| 29333497 | Work efficiency improvement of >90% after implementation of an annual inpatient blood products administration consent form. | BMJ Open Qual | 2018 |
| 30355798 | Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma. | Sci Transl Med | 2018 |